KCT0004781尚未招募未知
A study to assess the metabolic alterations of cholecalciferol (vitamin D3) after oral administration in elderly volunteers
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 65(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Koreans over 65 years of age at the time of the screening
- •2) A subject who weighs more than 50kg and weighs less than ±20% of his or her ideal body weight {height cm -100} X 0.9
- •3) A subject who has been found suitable for the study through physical examination and medical examination by interview with this study plan. i.e. subject who has no congenital or chronic disease and pathological symptoms or findings from a medical examination
- •4) Diagnosis laboratory test (blood chemistry test, urine test) and 12 electrode ECG results, those who have been deemed suitable for the study
- •5) A subejct who agree to take shading with clothing, hats and sunscreen (SPF30 or higher) for activities exposed to at least 1 hour of sunlight during the study period at least 10 days prior to the administration of the clinical study drug
- •6) A subject who agree to prohibit the intake of vitamin D supplements (cod-liver oil, salmon, tuna, catfish, mackerel, sardines, unagi, etc.) or foods (dairy products with enhanced vitamin D content) or vitamin D within at least 10 days from the date of clinical research medication
- •7) After hearing and fully understanding the detailed description of this clinical study, a subject who voluntarily decided to participate and agreed in writing to comply with the precautions
排除标准
- •1) A subject who has or has a history of clinically significant hepatobiliary system, kidney, nervous system, respiratory system, blood and tumor, endocrine system, urinary system, mental disease, musculoskeletal system, immune system, otolaryngology, cardiovascular system
- •2) A subject who has a past history of gastrointestinal diseases (e.g., dysphagia, esophageal disease, gastritis, duodenitis, ulcer, Crohn's disease, acute or chronic pancreatitis), and gastrointestinal operation (excluding simple appendicitis surgery or hernia surgery) that can affect the absorption of clinical medicine
- •3) Patients with esophageal disorders that delay esophageal transit, such as esophageal stenosis or achalasia
- •4) Patients who are unable to sit up or stand upright for more than 30 minutes or who are in long-term immobilization (recovery period after surgery, organ stabilizers, etc)
- •5) A subject with hypersensitivity or has a clinically significant history of hypersensitivity to drugs and other drugs (aspirin, antibiotics, etc) including vitamin D components
- •6) Patients with genetic problems such as galctose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption because they contain lactose intolerance
- •7) Patients with severe renal impairment (creatinine clearance less than 60 mL/min, calculated by the Cockroft-Gault equation from blood creatinint levels)
- •8) Untreated hypocalcemia patients (serum calcium < 7.0 mg/dL)
- •9) Hypercalcemia, hypercalciuria, kidney stones or history
- •Hypercalcemia: calcium levels in the blood exceed 1.2 times the normal upper limit
- •Hypercalciuria: When the ratio of calcium and creatinine in urine using single urine exceeds 0.2
- •10) AST or ALT exceeds 1.5 times the upper limit of the reference range or total bilirubin exceeds 1.5 times the upper limit of the reference range
- •11) Have a history of drug abuse
- •12) In case of administering metabolic enzyme induction or suppressing drug such as barbital medicine within 1 month
- •13) In case any specialty drugs, herbla medicines, OTC drugs, or vitamin drugs within 10 days prior to the start of this study are judged by the researchrs to be able to affect the safety of the subjects
- •14) A subject who participated in other clinical study and bioequivalent study within 6 months prior to the date of administration
- •15) Complete blood donation within 2 months prior to the date of administration, or component donation within 1 month, or received a blood transfusion within 1 month
- •16) permanent excessive drinking (greater than 21 units/week, 1 unit = 10 g of pure alcohol) or who cannot drink from 24 hours before admission until the last blood colleciton
- •17) More than 10 smokers a day on average over the last 3 months
- •18) A subject who is scheduled or unable to postpone dental treatment (extraction, orthodontics, neurotherapy, etc.) and selective surgery (beauty surgery, LASIK, LASEK, etc.) from the time the agreement is signed until the end of the study
- •19) A subject who deems the investigator unsuitable for participation in the clinical study for other reasons
研究者
相似试验
招募中
Unknown
Study of changes in the blood of patients of exogenous Cushing syndrome which is caused by use and misuse of steroids for a long timeCTRI/2023/09/057814Yenepoya University
已完成
不适用
An evaluation of the effect of chlorhexidine in combination with sodium perborate on gingivitis, plaque and tooth surface stainingCondition 1: gingivitis. Condition 2: tooth surface staining.Chronic gingivitisPosteruptive colour changes of dental hard tissuesIRCT201102245900N1Hamedan dental faculty40
招募中
不适用
Effect of a Diet with fewer Calories and a low-Meat diet in the metabolism of humansC18.452.394.750.149Type 2 Diabetes MellitusRBR-3hknrwHospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP
尚未招募
Unknown
utritional response to chyme reinfusion therapy in intestinal failure – a pilot studyIntestinal failureMalabsorptionMalnutritionDiet and Nutrition - Other diet and nutrition disordersOral and Gastrointestinal - Normal oral and gastrointestinal development and functionACTRN12623001254684Massey University12
进行中（未招募）
1 期
Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal JunctioEUCTR2014-000860-16-DETechnische Universität München Fakultaet fuer Medizin120